Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBIT Margin (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EBIT Margin for 5 consecutive years, with 36186.98% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 3541712.0% year-over-year to 36186.98%, compared with a TTM value of 229.41% through Dec 2025, down 1016854.0%, and an annual FY2025 reading of 229.41%, up 2646340.0% over the prior year.
  • EBIT Margin was 36186.98% for Q4 2025 at Aligos Therapeutics, up from 3827.4% in the prior quarter.
  • Across five years, EBIT Margin topped out at 36186.98% in Q4 2025 and bottomed at 105952.63% in Q3 2024.
  • Average EBIT Margin over 5 years is 5662.06%, with a median of 1594.24% recorded in 2022.
  • The sharpest move saw EBIT Margin crashed -10506726bps in 2024, then soared 10212524bps in 2025.
  • Year by year, EBIT Margin stood at 10340.05% in 2021, then surged by 98bps to 163.1% in 2022, then crashed by -317bps to 680.73% in 2023, then soared by 213bps to 769.86% in 2024, then surged by 4600bps to 36186.98% in 2025.
  • Business Quant data shows EBIT Margin for ALGS at 36186.98% in Q4 2025, 3827.4% in Q3 2025, and 1924.04% in Q2 2025.